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Abstract
Background: Approximately 2.7 million Americans are chronically infected with hepatitis C virus (HCV). HCV
patients with cirrhosis form the largest group of persons at high risk for hepatocellular carcinoma (HCC). Increased
oxidative stress is regarded as a major mechanism of HCV-related liver disease progression. Deficiencies in retinoid
and carotenoid antioxidants may represent a major modifiable risk factor for disease progression. This study aims to
identify key predictors of serum antioxidant levels in patients with HCV, to examine the relationship between
retinoid/carotenoid concentrations in serum and hepatic tissue, to quantify the association between systemic
measures of oxidative stress and antioxidant status, and to examine the relationship between retinoids and stellate
cell activation.
Methods: Patients undergoing liver biopsy (n = 69) provided fasting blood, fresh tissue, urine and completed a diet
history questionnaire. Serum and questionnaire data from healthy volunteers (n = 11), normal liver tissue from
public repositories and patients without liver disease (n = 11) were also collected. Urinary isoprostanes, serum and
tissue retinoid concentrations were obtained by UHPLC-MS-MS. Immunohistochemistry for αSMA was performed on
FFPE sections and subsequently quantified via digital image analysis. Associations between urinary isoprostanes,
αSMA levels, and retinoids were assessed using Spearman correlation coefficients and non-parametric tests were
utilized to test differences among disease severity groups.
Results: There was a significant inverse association between serum retinol, lycopene, and RBP4 concentrations with
fibrosis stage. Serum β-carotene and lycopene were strongly associated with their respective tissue concentrations.
There was a weak downward trend of tissue retinyl palmitate with increasing fibrosis stage. Tissue retinyl palmitate
was inversely and significantly correlated with hepatic αSMA expression, a marker for hepatic stellate cell activation
(r = −0.31, P < 0.02). Urinary isoprostanes levels were inversely correlated with serum retinol, β-carotene, and RBP4.
Conclusions: A decrease in serum retinol, β-carotene, and RBP4 is associated with early stage HCV. Retinoid and
carotenoid levels decline as disease progresses, and our data suggest that this decline occurs early in the disease
process, even before fibrosis is apparent. Measures of oxidative stress are associated with fibrosis stage and concurrent
antioxidant depletion. Vitamin A loss is accompanied by stellate cell activation in hepatic tissue.
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Background
The progression of hepatitis C virus (HCV) infection
can lead to cirrhosis and in some cases hepatocellular
carcinoma (HCC), which has limited treatment options
and poor prognosis. Approximately 2.7 million Ameri-
cans are chronically infected with HCV. HCV patients
with cirrhosis form the largest group of persons at high
risk for HCC [1–5]. Oxidative stress, resulting from
chronic inflammation, is purported to be a major mech-
anism for hepatic fibrosis and cirrhosis [6]. An imbal-
ance between production of reactive oxygen species and
antioxidant defense induces a number of pathophysio-
logical changes in the liver, including activation of hep-
atic stellate cells (HSCs), oxidative damage to lipids,
nucleotides and proteins, and initiation of proliferative
processes associated with regeneration. Vitamin A and
its carotenoid precursors are an important part of the
body’s antioxidant defense, due to their ability to scav-
enge and directly neutralize free radicals in the tissue. In
normal liver, quiescent HSCs are responsible for the
storage of more than 90 % of the body’s vitamin A re-
serves as retinyl esters. Upon chronic liver injury HSC
undergo activation, lose their capacity to store vitamin A
while acquiring contractile, proliferative and proinflam-
matory properties that are believed to play a major role
in fibrogenesis [7]. Hepatic αSMA expression in the
parenchyma is a marker of activated HSCs due to
their myofibroblast phenotype. However, it is uncertain if
retinoid loss is required for stellate cell activation and if
retinoid loss accelerates activation.
In this context, deficiencies in dietary antioxidants,
such as retinoids and carotenoids, could represent a
major modifiable risk factor for chronic liver disease
(CLD) progression. Two prospective epidemiological
studies evaluating the relationship between serum reti-
noids and liver cancer among subjects with chronic
hepatitis B found that higher pre-diagnostic serum ret-
inol was strongly associated with a subsequent reduced
risk of liver cancer [8, 9]. More recently, a large cohort
study in Finland observed that higher baseline serum
retinol and β-carotene were inversely associated, many
years later, with the incidence of liver cancer and death
from CLD [10]. Additionally, a randomized trial has
reported compelling evidence that polyprenoic acid, a
synthetic retinoid, reduced the incidence of second
primary liver tumors and prolonged survival in HCC
patients [11]. A small number of studies to date have
found that these serum micronutrients are depleted
in cirrhotic patients and only three studies to date
have assessed hepatic antioxidant levels in small and
generally heterogeneous populations of pre-cirrhotic
individuals [12–19].
Despite vast improvements in HCV treatment in recent
years, there are potential opportunities for therapeutic or
preventive strategies involving antioxidant repletion, par-
ticularly in patients who have progressed to cirrhosis even
if they achieve virologic cure [20–22]. These limitations
highlight a crucial need to develop adjuvant strategies to
prevent progression in high-risk individuals [23]. However,
supplementation with vitamin A itself must be approached
cautiously in individuals with liver disease, as hypervitamin-
osis A causes accelerated liver fibrosis and may also pro-
mote carcinogenesis [24]. Therefore, there is a need for
more information on the spectrum and causes of retinoid
and carotenoid depletion in the HCV-infected population,
so that optimal strategies for clinical trials can be identified.
Among HCV-infected persons, antioxidant depletion
could be explained by a combination of dietary, lifestyle,
and physiological factors. Apart from processes directly
linked to HCV infection, these factors include inad-
equate dietary antioxidant intake, smoking, alcohol in-
take or diabetes, all of which have been reported to
diminish defense against oxidative stress. The present
study aims to: a) determine the prevalence and predic-
tors of retinoid and carotenoid depletion in a well-
defined patient population, b) examine the relationships
between retinoid and carotenoid concentrations in
serum and hepatic tissue, c) quantify the association be-
tween systemic measures of oxidative stress and antioxi-
dant status, and d) examine the relationship between
antioxidant levels and stellate cell activation. We postu-
lated that lower retinoid and carotenoid concentrations
and higher levels of oxidative stress would be associated
with fibrosis stage among HCV-infected patients.
Methods
Study population
We conducted a cross-sectional study among patients
with HCV at the University of Illinois at Chicago (UIC)
and University of Chicago (UC). A total of 91 subjects
were included in this study; however not every subject
fulfilled every component of the study. We consented
and consecutively enrolled patients with confirmed HCV
undergoing percutaneous or transvascular liver biopsy
(n = 69) who provided fasting blood, fresh tissue, urine,
and completed a diet history questionnaire. At the time
of the biopsy, liver histology was staged into F0-4
according to the Batts-Ludwig scoring system. Subjects
with F0 were categorized as having no fibrosis. Subjects
with fibrosis stage 1–2 and fibrosis 3–4 were categorized
as mild/moderate and severe fibrosis, respectively. The
liver histology staging criteria was utilized to define
fibrosis stage in our analysis.
All biopsies were performed with 16 or 18-gauge nee-
dles; an average of 7.7 mm3 fresh tissue was taken from
the end of each core and snap frozen for research pur-
poses. We collected serum, urine, and questionnaire data
from healthy volunteers (n = 11). We obtained post-
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mortem normal liver tissue from the Cooperative Human
Tissue Network (CHTN) repository (n = 8); there was no
corresponding serum, urine and questionnaire data for
these individuals. The remaining controls included pa-
tients with no chronic liver disease (n = 3) who provided
serum, tissue, urine, and questionnaire data. The UIC and
UC Institutional Review Boards approved the study. An
informed consent to participate in the study was obtained
from participants.
Dietary assessment
The National Cancer Institute Diet History Question-
naire I (DHQ) was completed by all participants who
provided serum. The DHQ was subsequently analyzed
by the Diet*Calc Analysis Program (Version 1.4.3. Na-
tional Cancer Institute, Applied Research Program). This
program generated nutrient estimates based on fre-
quency and portion sizes over the past year. Approxi-
mate retinoid and carotenoid intake was calculated from
the DHQ. Pre-formed vitamin A is primarily found in
animal sources such as eggs, dairy produce, fish, and
meat. Carotenoids, which are found primarily in plant
foods, include α-carotene, β-carotene, β-cryptoxanthin,
lutein, and zeaxanthin; of those only α-carotene, and
β-carotene are pro-vitamin A carotenoids; i.e., vitamin
A precursors. To account for both pre-formed and
pro-vitamin A dietary sources, the recommended dietary
allowance for vitamin A is expressed in retinol activity
equivalents (RAE).
Serological measurements
Serum analyses were performed by the clinical pathology
laboratories at UIC. The serum chemistry panel included
liver function tests aspartate aminotransferase (AST),
alanine aminotransferase (ALT), international normal-
ized ratio (INR), albumin, total bilirubin, total protein,
BUN, hemoglobin, creatinine, and platelet count. Fasting
serum insulin, glucose, and high sensitivity C-reactive
protein, a marker of systemic inflammation (hs-CRP)
were measured in single batches on SYNCHRON®
Systems from Beckman Coulter (Pasadena, California).
Based on blinded duplicates from a quality control
pool of serum, intra-batch coefficients of variation
(CV) aliquots for fasting serum insulin, glucose, and
hs-CRP were 2.4, 0.65, and 0.98 %, respectively. Insulin re-
sistance was measured using the homeostatic model as-
sessment of insulin resistance (HOMA-IR). Predictive
markers of fibrosis, aminotransferase to platelet ratio
index (APRI) and Fibrosis 4 (FIB4) were calculated using
published formulas [25, 26].
Serum retinoid/carotenoid assays
Singlicate measurements of retinoids and carotenoids
in fasting serum samples were performed by using
atmospheric pressure chemical ionization mass spectrom-
etry as described previously, with the following changes
[27]. Ultrahigh pressure liquid chromatography-tandem
mass spectrometry (UHPLC-MS/MS) was carried out
using a Shimadzu (Kyoto, Japan) LCMS-8040 triple quad-
rupole mass spectrometer equipped with a Shimadzu
Shim-pack XR-ODSIII column (2.0 × 50 mm, 1.6 μm) at
35 °C. After holding at 5:95 (v/v) methyl-tert-butyl ether/
methanol for 0.3 min, a 0.45-min linear gradient was used
from 5 to 30 % methyl-tert-butyl ether at a flow rate of
0.6 mL/min. Carotenoids and retinoids were detected by
MS/MS during the same analysis using polarity switching
and the following selected reaction monitoring transitions:
lycopene m/z 536 to 467 (-), [13C10]-lycopene (internal
standard) m/z 546 to 477 (-), β-carotene m/z 536 to 536
(-), lutein m/z 551 to 135 (+), retinol and retinyl palmitate
m/z 269 to 93 (+).
Based on blinded replicates from a quality control pool
of serum, mean intra- and inter- batch CVs for retinol in
serum samples were 9.3 and 13.9 %, respectively. Aver-
age intra- and inter- batch CV for all serum retinoids
and carotenoids were 13.9 and 9.7 %, respectively.
The Relative Dose Response (RDR) test has been pro-
posed as a better alternative for determining vitamin A
deficiency compared to serum retinol. A retinol increase
of greater than 20 % following a challenge dose of retinyl
palmitate is considered a positive test indicating defi-
cient liver reserves. Serum delta RDR values were calcu-
lated according to the following formula: 100 A5−A0A5 . A0
is the serum retinol concentration at baseline, and A5 is
the serum retinol concentration at 5 h post-retinol dose.
Test participants provided serum for baseline retinol
levels after an overnight fast, and then ingested 1000
RAE of retinyl palmitate dissolved in corn oil on a
cracker. Serum retinol levels were measured again five
hours later. Of the 24 subjects who completed the RDR,
eleven had tissue available.
RBP4 measurement
Serum retinol binding protein 4 (RBP4) was measured in
duplicate using an enzyme-linked immunosorbent assay
(ELISA) (ALPCO Diagnostics, Salem, NH) according to
the manufacturer’s instructions. The kit utilized a poly-
clonal rabbit anti-RBP antibody.
Tissue retinoid/carotenoid assays
Hepatic tissue retinoid and carotenoid measurements
were performed using UHPLC-MS/MS as described
above, except that the tissue (0.5 to 5 mg) was homoge-
nized in 200 μl water and extracted twice using 600 μl
portions of ethanol/hexane (20:80; v/v) containing 0.1 %
butylated hydroxytoluene. The same protocol was used
for all of the hepatic tissue available. Based on adjacent
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samples from a random subject within each batch,
mean intra-batch CV for hepatic tissue retinyl palmi-
tate, β-carotene, and lycopene were 6.9, 10.0 and 4.1 %,
respectively.
Urinary isoprostanes
Urine concentrations of 8-iso-PGF2α, a marker of lipid per-
oxidation were measured using a rapid UHPLC-MS/MS
assay as described previously [28]. Based on anonymous
replicates from a quality control pool of urine, mean intra-
and inter-batch CV for the urinary isoprostanes measure-
ments were 6.4 and 7.8 %, respectively.
Immunohistochemistry
Tissue sections of 4 μm each were placed on charged
slides, dehydrated, and then deparaffinized. Immunostain-
ing was carried out using a BondRX (Lecia Biosystems,
Buffalo Grove, IL) autostainer with a mouse monoclonal
antibody for αSMA (DAKO, Clone 1A4) in a 1:2000
dilution for 15 min at room temperature to identify
HSC. The sections were then incubated in rabbit anti-
mouse IgG (Bond Polymer Refine Detection, Leica Biosys-
tems) for 20 min. No antigen retrieval was used for this
stain. Color reaction was developed using diaminobenzi-
dine (DAB) as the chromagen, followed by counterstain-
ing with hematoxylin. Positive and negative controls were
included in each batch.
Slides were scanned at 20× on an Aperio ScanScope®
CS whole-slide digital microscope (Leica Biosystems). A
digital draw tool was used to identify hepatic parenchy-
mal areas. Large vessels, inflammation, and artifacts
(e.g., folds, debris, etc.) were excluded from analysis.
αSMA quantitation was restricted to the hepatic paren-
chymal region to exclude αSMA positive cells (i.e., portal
fibroblasts and bone marrow derived collagen-producing
cells) in the portal region [29]. Definiens Tissue Studio®
3.6.1 (Definiens, Munich, Germany), a digital image ana-
lysis platform, was used to measure the percent positivity
of αSMA stain area within the hepatic parenchyma.
Statistical analysis
Frequency distributions of dietary intake, urinary iso-
prostanes, retinoid, and carotenoid concentrations were
examined for normality. Scatterplots and Spearman rank
correlation coefficients were used to examine relation-
ships among the variables of interest. A P-value of < 0.05
was considered statistically significant, and all tests were
two-sided. Analyses were performed using SAS Version
9.2 (SAS, Inc., Cary, NC).
Results
Table 1 shows selected demographics and clinical char-
acteristics of the study participants at both institutions
by fibrosis stage. Participants in the control group were
more likely to be white, overweight, and non-smokers.
There were no differences in ethnicity, BMI, smoking
status, or diabetes among the disease groups. The no
fibrosis group was more likely to be overweight or obese
compared to the mild/moderate fibrosis group (94 % vs
59 %). A majority of the HCV-positive subjects had ei-
ther genotype 1a (52 %) or 1b (38 %) as reported by
medical records. The median AST, APRI, and FIB-4
levels in disease subjects were positively associated with
the fibrosis stage (Additional file 1: Table S1). However,
hs-CRP concentrations were inversely and significantly
associated with fibrosis stage (P < 0.05) (Additional file 1:
Table S1).
Dietary intake of individual retinoids and carotenoids
did not differ between controls and HCV subjects. There
was evidence of a downward trend for total vitamin A
intake (expressed as retinol activity equivalents, RAE)
with increasing fibrosis stage, however this trend was
weak and not readily distinguishable from chance, as
shown in Fig. 1. Total vitamin A, or individual retinoid
and carotenoid intake also did not differ by fibrosis stage
or predictive markers of fibrosis (APRI and FIB-4). Mean
total vitamin A intake was 1182 and 1295 mcg RAE for
men and women, respectively; values well above the gen-
eral population based on data from NHANES III (682
and 606 mcg RAE, for men and women, respectively).
Total vitamin A or individual retinoid and carotenoid
intake levels were not associated with BMI, smoking
status, alcohol consumption, or insulin resistance.
Dietary β-carotene and lutein intake were positively and
significantly correlated with their respective serum con-
centrations (β-carotene: r = 0.24, P = 0.05; lutein: r = 0.33,
P < 0.01). However, total vitamin A intake did not correl-
ate with serum retinol concentrations (r = 0.07, P = 0.53).
Similarly, no relationships between intake and serum were
observed for other dietary carotenoids. Tissue retinoid
and carotenoid levels were not associated with dietary in-
take (data not shown). Figure 2 shows that serum retinol
and hepatic retinyl palmitate concentrations, the respect-
ive dominant forms of vitamin A in serum and liver, were
not correlated (r < 0.01, P = 0.99). However, serum and tis-
sue concentrations of β-carotene (r = 0.56, P < 0.01) and
lycopene (r = 0.77, P < 0.01) were moderately correlated in
this study population.
Serum retinol and RBP4 concentrations were signifi-
cantly lower in HCV subjects compared to controls,
although no HCV subjects met the standard serum criteria
for vitamin A deficiency (<200 ng/mL). Figure 3 shows a
significant downward trend of serum retinol and RBP4
concentrations with increasing hepatic fibrosis. Similar re-
lationships were also observed for serum β-carotene, lyco-
pene, and lutein concentrations (Fig. 4). No relationships
were observed for serum retinoids and carotenoids with
either APRI or FIB-4 scores (data not shown). However,
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RBP4 levels were inversely and significantly correlated
with AST and ALT levels (r = −0.34, P < 0.01; r = −0.28,
P = 0.015, respectively). Individual retinoid and carot-
enoid concentrations did not vary according to sex,
BMI, smoking status, alcohol consumption, or
insulin resistance. Of the 24 HCV participants who
completed the RDR test, two of them had RDR
values >20 %, suggestive of a vitamin A deficiency.
There was no apparent relationship between delta
RDR retinol concentrations and retinyl palmitate
concentrations in hepatic tissue (Spearman r = −0.03,
P = 0.92) or fibrosis stage (data not shown).
Hepatic retinyl palmitate levels were lower in control
tissue samples, which were mostly obtained post-mortem,
compared to diseased subjects (Wilcoxon P = 0.04). In
contrast, hepatic lycopene and β-carotene concentrations
were higher in controls compared to diseased subjects
Table 1 Selected characteristics of the study population by fibrosis stage
Characteristics Control No fibrosis Mild/Moderate fibrosis Severe fibrosis Total P-value* P-value**
n = 22 n = 18 n = 34 n = 17 n = 91
Age - Median (IQR) 45 (42–54) 55 (51–62) 53 (48–58) 56 (53–57) 53 (46–58) 0.17 0.17
Gender
Male 12 6 18 10 46 0.42 0.27
Female 10 12 16 7 45
Ethnicity
Asian 0 0 1 0 1 <0.01 0.68
Black 2 12 17 7 38
White 18 6 15 9 48
Unknown 2 0 1 1 4
BMI
< 25 0 1 13 4 18 0.02 0.11
25–30 5 9 12 7 33
> 30 9 8 8 6 31
Unknown 8 0 1 1 10
Smoking Status
Never 17 7 10 7 41 0.02 0.60
Former 2 7 11 7 27
Current 3 4 13 3 23
Diabetes
Yes 3 2 3 4 12 0.56 0.33
No 19 16 31 13 79
HCV Genotype
1 – 11 29 13 53 0.15 0.15
2 – 1 0 0 1
3 – 0 0 1 1
Unknown – 6 5 3 14
*P-values are Fisher exact (2-tailed) for comparison of proportions and Kruskal-Wallis test for comparison of medians amongst all groups
**P-values are Fisher exact (2-tailed) for comparison of proportions and Kruskal-Wallis test for comparison of medians amongst diseased groups
Bold face represents statistically significant values
Fig. 1 Boxplots (Whiskers = 10th and 90th percentile) of total
vitamin A intake (mcg retinol activity equivalents) by fibrosis stage
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Fig. 2 Scatterplots showing correlations (Spearman r) between a Serum retinol and tissue retinyl palmitate (n= 60), b Serum and tissue β-carotene (n= 58),
and c Serum and tissue lycopene (n= 60)
Kataria et al. BMC Gastroenterology  (2016) 16:30 Page 6 of 12
(Wilcoxon P = 0.07, P = 0.34, respectively). There was a
weak inverse relationship between hepatic retinyl palmi-
tate concentration and fibrosis stage among all subjects
(P = 0.36) (Fig. 5). Furthermore, hepatic β-carotene and
lycopene concentrations showed a weak downward trend
with increasing fibrosis stage. Hepatic retinyl palmitate was
positively and significantly correlated with APRI, FIB-4,
ALT, and AST (r = 0.27, P = 0.03; r = 0.29 P = 0.02; r = 0.30,
P = 0.015; and r = 0.24, P = 0.05, respectively). These rela-
tionships were not observed for tissue carotenoids.
Parenchymal αSMA expression in hepatic tissue ap-
peared to increase only among subjects with fibrosis 3–4
(Additional file 2: Figure S1) (Wilcoxon P = 0.12). αSMA
expression was not associated with serum retinol concen-
trations (r = −0.03, P = 0.79). However, αSMA expression
was inversely and significantly correlated with tissue retinyl
palmitate concentrations (r = −0.31, P = 0.013) (Fig. 6). This
relationship was not observed for any other tissue ca-
rotenoids (data not shown). In particular, hepatic
lycopene levels were not correlated with αSMA
expression (r = −0.03, P = 0.81).
Urinary isoprostane levels were positively and signifi-
cantly associated with fibrosis stage (Additional file 3:
Figure S2). Serum retinol, β-carotene, and RBP4 concen-
trations were all inversely and significantly associated
with urinary isoprostane concentrations. Tissue retinoid
concentrations were not correlated with urinary isopros-
tane levels (Table 2). However, both serum and hepatic
lycopene were suggestively correlated (r = −0.18, P = 0.12;
r = -0.22, P = 0.09, respectively).
Discussion
Our results confirm that depletion of vitamin A, lyco-
pene, and β-carotene is widespread among patients with
chronic HCV infection. This phenomenon seems to
occur early in the disease process, even before fibrosis is
apparent, and cannot be explained, based on our results,
by diet, obesity, alcohol intake, smoking, or insulin re-
sistance. Inverse associations with fibrosis progression
were more apparent for serum as opposed to hepatic
levels of retinoids and carotenoids, and were especially
clear for serum retinol and RBP4. While we found rela-
tively strong correlations between serum and liver tissue
for lycopene and β-carotene, hepatic retinyl palmitate
was poorly correlated with serum retinol, suggesting dif-
ferential factors modulating these levels [17, 18]. It is
also possible that declines in serum retinoids appear
earlier in the disease process than declines in hepatic
stores. We further observed that depletion of serum an-
tioxidants is linked to increasing levels of urinary iso-
prostanes, which are reflective of systemic oxidative
stress due to lipid peroxidation. An important finding
was that hepatic retinyl palmitate levels were signifi-
cantly and inversely associated with stellate cell activa-
tion, as measured by αSMA expression in liver biopsy
specimens. Taken together, results from this cross-
sectional analysis support the hypotheses that depletion
of retinoid and carotenoid antioxidants occurs early in
the disease process and that this depletion parallels an
increase in oxidative stress and evidence of hepatic
stellate cell activation.
In the present study, the reduced serum retinol levels
associated with CLD progression were well above the
widely accepted WHO cut-off point of 200 ng/mL for
vitamin A deficiency. Moreover, only two of the HCV par-
ticipants had a positive RDR test, indicating inadequate
liver vitamin A reserve. Serum retinol and β-carotene
levels in our HCV participants were also generally com-
parable to the NHANES III participants, a nationally rep-
resentative sample of the US population [30]. Reduced
dietary intake of retinoids and carotenoids do not appear
to be responsible for the observed associations with fibro-
sis stage, which could be the result of diminished storage
capacity, increased metabolism or defective mobilization
Fig. 3 Boxplots (Whiskers = 10th and 90th percentile) for serum concentrations of a retinol and b RBP4 by fibrosis stage. *P < 0.05 compared to
Control **P < 0.05 compared to Fibrosis 0 group
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Fig. 4 Boxplots (Whiskers = 10th and 90th percentile) for serum
concentrations of a β-carotene, b lycopene, and c lutein by fibrosis
stage. *P < 0.05 compared to control group
Fig. 5 Boxplots (Whiskers = 10th and 90th percentile) for tissue
concentrations of a retinyl palmitate, b β-carotene, and c lycopene
by fibrosis stage. 1P-trend excludes control group
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of retinol due to impaired RBP4 synthesis [15, 31, 32]. In
any event, a cross-sectional study such as this is unable to
determine if antioxidant depletion is a causal factor in fi-
brosis progression, or simply an epiphenomenon that ac-
companies progression.
The current study supports prior evidence that serum
RBP4 concentrations are inversely related to disease sever-
ity in HCV patients [33, 34]. We observed a high correl-
ation between serum RBP4 and retinol (r = 0.78, P < 0.001).
Serum RBP4 measured by an enzyme immunoassay might
be a feasible and cost-effective alternative for assessing
vitamin A status. No association was detected between
RBP4 levels and albumin, suggesting that generally de-
creased hepatic protein synthesis did not contribute to the
reduction in RBP4. However, impaired mobilization of
hepatic stores could explain the decrease of RBP4 seen in
CLD. Increased serum RBP4 has been reported to
contribute to insulin resistance associated with type 2 dia-
betes and obesity, which are possible risk factors for CLD
progression [35]. We observed no correlation between
RBP4 concentrations and BMI, glucose, or insulin levels.
The possible effects of reduced RBP4 levels on insulin re-
sistance among CLD patients might warrant further study.
A small number of studies have evaluated serum and
tissue concentrations of dietary antioxidants in patients
with CLD; although these have focused on more severe,
later stage disease. The lack of correlation between
serum retinol and tissue retinyl palmitate could be ex-
plained by impaired release of retinol from damaged he-
patocytes or by the presence of homeostatic mechanisms
that maintain hepatic retinol until vitamin A stores are
severely depleted. We did not observe a definite decline
in hepatic retinyl palmitate concentrations with increas-
ing disease severity in earlier stages of CLD. Yadav et al.
reported lower levels of retinyl esters in 20 HCV pa-
tients compared to controls [17]. In our study, however,
the lower concentration in controls could have been
caused by the degradation of retinyl palmitate into ret-
inol in the cadaver tissue by endogenous esterase. In-
deed, we observed higher levels of hepatic retinol in the
control subjects (data not shown). It has been reported
that patatin-like phospholipase domain-containing pro-
tein 3 (PNPLA3) regulates retinyl ester release. Specific-
ally, carriers of the I148M mutation in PNPLA3 have
intracellular hepatic retention of retinyl palmitate [36].
Subsequently, Mondul et al. found in NAFLD patients
that carriers of the PNPLA3 I148M mutation have lower
circulating levels of retinyl palmitate and RBP4 but not
β-carotene concentrations [37]. PNPLA3 is also a strong
determinant for HCC [38]. Taken together, it is possible
that the intracellular retention of vitamin A is contrib-
uting to fibrosis progression and HCC. The observed
reduction in serum Vitamin A levels may reflect a
pseudo-deficiency. Future studies investigating the
PNPLA3 genotype in this population may provide
further insight. The reason for the positive relationship
between hepatic retinyl palmitate and liver enzymes is
unclear, but this relationship would also be consistent
with mechanisms that favor retention of vitamin A in
the presence of early but ongoing liver damage.
Lycopene cannot be converted to vitamin A and thus
it presents an attractive potential alternative for antioxi-
dant supplementation in CLD. Adverse effects have not
been reported with consuming lycopene supplements or
high amounts of lycopene-rich foods [39, 40]. We ob-
served an inverse relationship of serum lycopene levels
with fibrosis stage. Moreover, unlike vitamin A, there
was also a strong correlation between serum and hepatic
lycopene levels, thus indicating that dietary supplemen-
tation could result in higher hepatic lycopene concentra-
tions. Yuan, et al. demonstrated an inverse association
Fig. 6 Scatterplots showing correlations (Spearman r) between tissue
retinyl palmitate and % marker area of αSMA protein expression (n= 65)
Table 2 Spearman correlations between urinary isoprostanes,
serum and tissue retinoids/carotenoids
Urinary isoprostanes
(ng/mg creatinine)





RBP4 (ug/L) −0.25 0.03




Retinyl Palmitate −0.03 0.79
Bold face represents statistically significant values
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between lycopene concentration in baseline serum and
risk of developing HCC in China. Lycopene is a potent
carotenoid antioxidant that is also thought to affect
processes related to mutagenesis, carcinogenesis, cell
differentiation, and proliferation [41, 42]. Epidemiological
data suggest that lycopene may act as a chemopreventive
agent for many cancer types such as prostate, breast, and
lung [43]. In vitro studies have observed that lycopene can
inhibit mouse and human hepatocytes by inducing cell
cycle arrest [44, 45]. However, dietary lycopene did not
prevent liver cancer in an in vivo model of spontaneous
hepatocarcinogenesis [46]. These discrepant results war-
rant further investigation.
Serum hs-CRP is synthesized by hepatocytes in response
to inflammation and is regulated by pro-inflammatory
cytokines such as IL-6. In a recent cohort analysis in
China, higher serum CRP levels at baseline were associ-
ated with liver cancer incidence and death from CLD [47].
As such, we hypothesized that higher levels of hs-CRP
would occur with increasing fibrosis stage. However, in
this study, hs-CRP concentrations decreased with increas-
ing fibrosis stage. While these findings are counterintui-
tive, a few smaller studies have suggested similar results
[48–50]. Nasciemento, et al. observed lower hs-CRP
to IL-6 ratio compared to controls, suggesting that
IL-6 stimulation of CRP production in the liver might
be mitigated by HCV [48]. It appears that CRP production
is affected early during the natural history of HCV infec-
tion, thus negating its utility as a biomarker of inflamma-
tion in this population.
F2-isoprostanes are a sensitive and validated urinary
marker of systemic oxidative stress due to lipid peroxida-
tion. In our study, smokers had higher isoprostane levels
compared to non-smokers. Our data indicate a positive as-
sociation between urinary isoprostane concentrations and
fibrosis stage. To our knowledge, this extends beyond
previous data that have shown patients with CLD and
cirrhosis have increased isoprostane levels compared
to controls [16]. As hypothesized, we observed a signifi-
cant inverse association of F2-isoprostanes with serum ret-
inol, β-carotene, and RBP4 levels. However, tissue retinoid
and carotenoid levels were not associated with urinary iso-
prostane levels with the possible exception of lycopene.
Urinary isoprostanes are a measure of total body lipid per-
oxidation, and therefore do not reliably reflect oxidative
stress in the target organ.
As we expected, subjects with moderate to severe fibrosis
had higher levels of αSMA expression in hepatic tissue
compared to subjects with mild fibrosis or none at all.
Thus, it appears that HSC activation might not be apparent,
at least by immunohistochemical technique, until substan-
tial fibrosis is present. Our data indicate that vitamin A de-
pletion could occur prior to development of significant
fibrosis and evidence of HSC activation. The hepatic
vitamin A depletion might be attributable to either
loss of storage capacity or increased consumption via
autophagy. Increased metabolism of vitamin A drop-
lets through autophagic mechanism generates sub-
strates needed for energy intensive pathways to meet
the metabolic demands of proliferation, fibrogenesis,
and contractility [51].
This is the first comprehensive analysis to examine the
interrelationships among dietary, serum, and hepatic
levels of retinoids and carotenoids with early progression
of disease in HCV patients. The present study, to our
knowledge, is the largest to date to quantitate hepatic
retinoids and carotenoids. In addition, the study benefit-
ted from quantitative image analysis that provided ob-
jective and reproducible measures of αSMA expression
in liver biopsy specimens. However, certain limitations
are acknowledged including, a limited sample size for
specific subgroups and a cross sectional design that can-
not be used to infer causal direction. Unfortunately, we
were unable to administer the RDR to more patients due
to the additional blood sample required five hours after
the initial retinyl ester dose. Additionally, the post-
mortem tissue samples of normal liver were not ideal as
they could have undergone artifactual changes in retin-
oid and carotenoid concentrations.
Findings from this study could be applicable to the
emerging epidemic of obesity-related non-alcoholic fatty
liver disease (NAFLD) and non-alcoholic steatohepatitis
(NASH) [52]. Oxidative stress is believed to play a key
role in these disease processes, similar to HCV-related
liver disease. Currently, there are no specific therapies
for NAFLD beyond dietary modifications and exercise.
Lower levels of retinoids have been implicated in
NAFLD. Transgenic mice with impaired retinoid signal-
ing develop steatohepatits and eventually HCC [23]. It
has also been found that NAFLD patients have higher
levels of oxidative stress and lower vitamin A intake, in-
dependent of metabolic syndrome status, suggesting that
adequate vitamin A intake is important in protecting
against oxidative stress in NAFLD patients [53].
Conclusions
In conclusion, a decrease in serum retinol, β-carotene,
and RBP4 is associated with early stage HCV. Retinoid
and carotenoid levels decline as disease progresses, and
our data suggest that this decline occurs early in the dis-
ease process, even before fibrosis is apparent. Measures of
oxidative stress are associated with fibrosis stage and con-
current antioxidant depletion. Vitamin A loss is accom-
panied by stellate cell activation in hepatic tissue. Our
data highlight the potential importance of dietary retinoids
and carotenoids as determinants of progression in early
chronic liver disease and support the need for mechanistic
studies leading to well-designed intervention studies.
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